$VRDN

Viridian Therapeutics, Inc.\DE

Viridian Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and rare diseases, particularly autoimmune diseases. It develops therapies through internal research and discovery and in-licensing, with capabilities in protein and antibody engineering, biologics manufacturing, clinical development and commercialization. Its pipeline includes veligrotug, an intravenous IGF-1R antibody for thyroid eye disease (TED), and elegrobart, a subcutaneous IGF-1R candidate for TED designed for infrequent dosing and at-home administration. Viridian also develops FcRn inhibitors VRDN-006 and VRDN-008 for potential use in autoimmune disorders, and an anti-TSHR candidate for TED and Graves’ disease. Viridian is preparing commercial infrastructure, including sales and marketing, market access, patient services and commercial operations. It holds worldwide commercialization rights to veligrotug and elegrobart, excluding Japan and the greater area of China. The company is headquartered in Waltham, Massachusetts.

AlphAI earnings readThird quarter 2026 · NOV 4Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business ProgressVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
2
0

No SEC Form 4 filings for $VRDN in the last 30 days.

See all $VRDN insider activity →
Med

Viridian Metals raises $5.77M in oversubscribed financing

Viridian Metals Inc. (CSE:VRDN, OTCQB:VIRMF) raised $5.77M in an oversubscribed private placement, exceeding its initial $5M target. The company issued 7.3M common shares and warrants, with proceeds earmarked for Canadian exploration and general corporate purposes. An insider participated, and finder's fees were paid. Securities are subject to a hold period until March 18, 2027.

A 450% revenue beat, a 20%+ gain: the biotech our AI models picked first

Viridian Therapeutics (VRDN) reported Q3 2026 revenue of $25.75M, beating consensus by 450.2%, driven by its FDA-approved thyroid eye disease treatment. Shares rose 9.09% premarket. The company has $955.2M in cash and expects a BLA submission for another drug in Q1 2027. Investing.com's AI models picked VRDN in November, and shares are up 20.92% since then.

Viridian Therapeutics Earnings Call Highlights Lumvoa Momentum

Viridian Therapeutics (VRDN) reported Q3 earnings, highlighting Lumvoa's first-quarter revenue of $24.7M and over 100 patients treated. Management emphasized strong commercial execution, early payer progress, and a solid financial position with $955M in cash. The company remains on track for elegrobart's BLA submission in Q1 2027 and expects pipeline updates this quarter.

VRDN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning VRDN (Viridian Therapeutics, Inc.\DE). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.

Recent VRDN coverage spans earnings, financial news and technology.

What's driving VRDN

AlphAI scores every news story that mentions VRDN with an AI model for sentiment and relevance, and aggregates insider trades from Viridian Therapeutics, Inc.\DE's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VRDN

Score

Viridian Therapeutics Earnings Call Highlights Lumvoa Momentum

Viridian Therapeutics (VRDN) reported Q3 earnings, highlighting Lumvoa's first-quarter revenue of $24.7M and over 100 patients treated. Management emphasized strong commercial execution, early payer progress, and a solid financial position with $955M in cash. The company remains on track for elegrobart's BLA submission in Q1 2027 and expects pipeline updates this quarter.

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

$VRDNMedAI 8/10Clinical / regulatory· topline data

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut

Viridian Therapeutics (VRDN) reported Q3 2026 earnings, highlighting Lumvoa's strong debut with $24.7M revenue driven by patient demand. The company secured payer coverage for 30% of covered lives, aiming for broader coverage in 6-9 months. Management expects Q4 growth and competitive VRDN-008 data. Lumvoa's launch success may inform the strategy for elegrobart (Ele) BLA submission.

Related tickers